Willingness to report treatment-related symptoms of immunotherapy among patients with non-small cell lung cancer
Bibliographic Data
| ID | 15299652 |
|---|---|
| Authors | Mona L Martin (0000-0001-6899-2139, Gramercy Research Group (United States), corresponding author), Helena Chung (0000-0001-5088-9889, AstraZeneca (United States)), Anna Rydén (0000-0001-8106-5751, AstraZeneca (Sweden)) |
| Year | 2021 |
| Volume | 31 |
| Issue | 4 |
| Pages | 1147-1155 |
| Publication date | 2021-08-12 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Quality of Life Research (JOURNAL) |
| Journal identifiers | ISSN: 0962-9343 • E-ISSN: 1573-2649 |
| Publisher | Springer Science+Business Media (PUBLISHER • DE) |
| DOI | 10.1007/s11136-021-02966-3 |
| PMID | 34383226 |
| OpenAlex | W3190257187 |
| Language | EN |
| Citations received | 1 |
| References cited | 8 |
Patients have a range of reasons for not reporting their treatment-related symptoms when undergoing immunotherapy for NSCLC. Reasons are more strongly related to determination of the severity versus manageability of patients' experiences of symptoms than they are to the fear of having treatment discontinued
Cancer · Immunotherapy · Intensive care medicine · Lung cancer · Pathology · Public health · Quality of life (healthcare · Quality of Life Research · Cancer Immunotherapy and Biomarkers · Lung Cancer Research Studies · Medicine · Neutropenia and Cancer Infections · Nursing · Internal Medicine · Oncology
| Citations per year | 0.25 |
|---|---|
| Citation span | 2022 - 2022 (1) |
| Highly cited | No |